Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19762
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMiller, Aaron E-
dc.contributor.authorXu, Xianhao-
dc.contributor.authorMacdonell, Richard A L-
dc.contributor.authorVucic, Steve-
dc.contributor.authorTruffinet, Philippe-
dc.contributor.authorBenamor, Myriam-
dc.contributor.authorThangavelu, Karthinathan-
dc.contributor.authorFreedman, Mark S-
dc.date2018-10-20-
dc.date.accessioned2018-11-04T23:50:37Z-
dc.date.available2018-11-04T23:50:37Z-
dc.date.issued2019-01-
dc.identifier.citationJournal of Clinical Neuroscience 2019; 59: 229-231-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19762-
dc.description.abstractIn the phase 3 TOWER (NCT00751881) study, teriflunomide 14 mg significantly reduced annualized relapse rate (ARR) and risk of 12-week confirmed disability worsening (12-w CDW) vs placebo in patients with relapsing forms of MS (RMS). The TOWER population included an appreciable proportion of Asian patients. Reductions in ARR and 12-w CDW associated with teriflunomide 14 mg were comparable between the Asian and overall populations, as were the rates for adverse events and serious adverse events, with no new or unexpected safety findings. These observations provide further evidence to support the clinical benefits and safety profile of teriflunomide in a broad range of patients with RMS.-
dc.language.isoeng-
dc.subjectClinical trial-
dc.subjectDisease-modifying therapy-
dc.subjectMultiple sclerosis-
dc.subjectPhase 3-
dc.subjectSubgroup analysis-
dc.subjectTeriflunomide-
dc.titleEfficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of Clinical Neuroscience-
dc.identifier.affiliationMultiple Sclerosis Research Unit, Department of Neurology, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canadaen
dc.identifier.affiliationDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States-
dc.identifier.affiliationDepartment of Neurology, Beijing Hospital, Beijing, China-
dc.identifier.affiliationDepartment of Neurology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationFaculty of Medicine, University of Sydney, Sydney, Australia-
dc.identifier.affiliationR&D, Sanofi, Chilly-Mazarin, France-
dc.identifier.affiliationGlobal Pharmacovigilance & Epidemiology, Sanofi, Chilly-Mazarin, France-
dc.identifier.affiliationBiostatistics, Sanofi, Cambridge, MA, United States-
dc.identifier.doi10.1016/j.jocn.2018.09.012-
dc.identifier.pubmedid30348586-
dc.type.austinJournal Article-
local.name.researcherMacdonell, Richard A L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

32
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.